Serum Natrium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution
Table 1
Patient and treatment characteristics.
Imatinib n = 80 (%)
Sunitinib n = 32 (%)
Sex
Male
51 (64)
10 (31)
Female
29 (36)
22 (69)
Age, years
Median (years)
63
61
Range
30–87
40–85
Performance status
0
54 (68)
24 (75)
1
18 (22)
6 (19)
2
7 (9)
1 (3)
3
1 (1)
1 (3)
Concomitant disease
No
45 (56)
21 (66)
Yes
35 (44)
11 (34)
Prior malignancy
No
72 (90)
28 (88)
Yes
8 (10)
4 (12)
Primary treatment
Surgery
49 (61)
22 (69)
No prior surgery
31 (39)
10 (31)
Start dose of imatinib/sunitinib
800 mg/50 mg
10 (13)
10 (31)
400 mg/37,5 mg
69 (86)
19 (60)
200 mg/25 mg
1 (1)
3 (9)
Permanent reduction of start dose
No
61 (76)
25 (78)
Yes
19 (24)
7 (22)
Reason for reduction of start dose
Haematological
2 (11)
Musculoskeletal
2 (11)
3 (43)
Multisystem
1 (5)
Dermatological
7 (37)
3 (43)
Gastrointestinal
6 (31)
Other
1 (5)
1 (14)
Response(a)
CR
3 (4)
PR
47 (59)
13 (41)
SD
16 (20)
13 (41)
PD
13 (16)
3 (9)
Death before evaluation
1 (1)
3 (9)
Progression(b)
No
26 (33)
8 (25)
Yes
52 (65)
19 (59)
Not evaluable
2 (2)
5 (16)
Local treatment
No
40 (77)
17 (89)
Yes
12 (23)
2 (11)
(a)Best response at any time during treatment. CR: complete response, PR: partial response, SD: stable disease, PD: progression of disease.
(b)Progression at the time of evaluation.
